Aspects of Heart Failure in Patients with Ischemic Heart Disease after Percutaneous Coronary Revascularization with Polymer-coated Drug-Eluting Stents versus Bare-Metal Stents

MARIANA TUDORAN, CRISTINA TUDORAN*, TUDOR CIOCARLIE, GHEORGHE NUCSOP POP, MARCEL MIHAI BERCEANU-VADUVA, DANA EMILIA VELIMIROVICI*, ABU AWWAD AHMED, DELIA MIRA BERCEANU-VADUVA
University of Medicine and Pharmacy Victor Babes, 2 Efimie Murgu Sq., 300041, Timisoara, Romania

Percutaneous coronary revascularization (PCR) with polymer-coated drug-eluting stents (DES) or bare-metal stents (BMS) is considered the standard therapy in advanced ischemic heart disease (IHD). Despite revascularisation, many of these patients subsequently develop heart failure with reduced ejection fraction (HFrEF). We analysed 51 patients with IHD, treated by PCR and insertion of DES and/or BMS who later developed HFrEF. Patients with DES where more likely women, of younger age and a higher incidence of diabetes mellitus compared to patients with BMS who were generally men, of older age and had more frequently acute ST-elevation myocardial infarction (STEMI) as indication for PCR. Although patients with DES had more severe IHD, their EF was higher, possibly due to the benefits offered by the DES.

Keywords: ischemic heart disease, polymer-coated drug-eluting stent, bare-metal stent, heart failure with reduced ejection fraction

Ischaemic heart disease (IHD) represents the most common cause of death and of HFrEF in the developed world [1]. The most effective treatment consists in a successful revascularization of the affected myocardium, realised either by PCR with insertion of stents, or by coronary artery by-pass graft (CABG) [2].

Heart failure secondary to IHD presents an increasing incidence because of the improved survival, attributed to the success of revascularisation by primary PCR in acute myocardial infarctions, but resulting often in left ventricular (LV) remodelling and chronic myocardial dysfunction. The best medical treatment of these patients represents a debated topic in the medical literature [3]. Despite the best medical therapy of HFrEF according to guidelines [3], many patients remain symptomatic, with increased morbidity and mortality raising the issue of a new revascularization strategy. Currently, CABG is recommended over PCR for younger patients, with multivessel IHD and severely reduced LV function [1]. This procedure is associated with an increased perioperative risk. PCR involves a much lower risk and the development of more performant DES, treated with immunosuppressive and antiproliferative drugs, with an advanced polymer coating, could improve the evolution of these patients [4].

The aim of this study is to evidence with factors are associated with the presence of HFrEF in patients with IHD treated by PCR and insertion of at least one stent and if there are differences between patients with DES versus those with BMS.

Experimental part

DES versus BMS

DES are considered superior to BMS for the treatment of IHD, most statistical analyses indicating lower rates of major adverse cardiac events [5, 6]. BMS consist only of a metal structure. DES consist of three parts - the stent platform, the polymer coating that binds the drug to the stent and releases drug into the arterial wall by contact transfer, and sometimes a top coat to slow down the release of the drug and extend its effect. The necessity of polymers on DES platforms is dictated by the need of an adequate amount and optimal release of the antiproliferative drugs for achieving ideal DES performance.

Polymers selected to be used as a drug carrier should share the following features: be biocompatible; do not interact with the drug; provide a platform for appropriate drug-eluting kinetics; behave biologically inert after the drug has been released.

One to three or more layers of polymer are used for the coating: a base layer for adhesion, a main layer that holds and elutes (releases) the drug into the arterial wall by contact transfer, and sometimes a top coat to slow down the release of the drug and extend its effect. The necessity of polymers on DES platforms is dictated by the need of an adequate amount and optimal release of the antiproliferative drugs for achieving ideal DES performance. Polymers selected to be used as a drug carrier should share the following features: be biocompatible; do not interact with the drug; provide a platform for appropriate drug-eluting kinetics; behave biologically inert after the drug has been released.

Fig. 1. Structure of a polymer-coated drug-eluting stent and of the polymer layers
completely eluted, and be mechanically stable at long-term in the dynamics of coronary circulation milieu. Various permanent (biostable) and biodegradable polymers have been used on DES platforms with various results which are still in testing in clinical trials [7-11], (table 1).

Patients group
This study was conducted on 51 patients, aged between 50 and 75 years, mean age 63.74 ± 6.69 years, with angiographically confirmed IHD, treated by PCR and implantation of at least one stent. 28 of them were men and 23 women. Subsequently, they developed HFrEF, treated with medication. During January-December 2018, they were either admitted for decompensated heart failure in the Cardiology Clinic or/and followed in the Ambulatory of our hospital.

They were divided in two groups:
- Group A—the DES group: included 18 patients who received at least one DES during any revascularisation procedure, regardless of whether they had received another type of stent at any time;
- Group B—the BMS-group: included all patients with other types of stents except DES.

Cardiologic evaluation
The diagnostic of HFrEF was based on the presence of symptoms and clinical signs suggestive for heart failure and on the assessment of a reduced ejection fraction (EF) of under 39% by echocardiography. All echocardiographic examinations were performed with an Acuson Sequoia C 512 echocardiograph by the same echocardiographist in order to avoid inter-observer differences. On the echocardiography, after a regular exam of cardiac morphology and function, we assessed the ejection fraction (EF) of the LV by using the Simpson method (normal over 55%).

Statistical methods
Data analysis was performed using SPSS v.25 (Statistical Package for the Social Sciences, Chicago, IL, USA). Continuous variables were presented as mean and standard deviation (SD) or median and interquartile range (IQR), and categorical variables were presented as frequency and percentages. The results of the normality test (Shapiro-Wilk) showed a non-Gaussian distribution, reason why we continued to use nonparametric tests. To evaluate the proportion of stenting indication, associated conditions and risk factor in table 1 we used Fisher’s exact test. To compare patients’ characteristics in Table 2 we used the Mann-Whitney U test. A p value of less than 0.05 was considered to indicate a statistically significant difference.

The study was approved by the Ethics Committee of our hospital and all patients signed a written informed consent.

Results and discussions
All fifty-five patients included in our study had angiographically confirmed IHD and underwent one or more PCR with implantation of at least one stent. They were divided in two groups according to the type of stent. The main indications for PCR and stenting, associated diseases and risk factors, in both groups are illustrated in table 2 and the results of clinical and echocardiographic evaluations are presented in table 3.

On average, as compared to patients with BMS, patients with DES were younger (p=0.004) and more likely to be women (61.11%); they also had a higher prevalence of diabetes mellitus (p<0.001), systemic hypertension,
hypercholesterolemia (p=0.038) and renal dysfunction. Multivessel disease and stable angina were the main indications for PCR. 27.77% of patients with DES had repeated PCR, and a higher number of stents, compared to those with BMS. Patients with BMS were older, were more likely to be men (63.63%) and more often had primary PCR for acute STEMI as indication for stenting (75.75%).

All patients included in our study had HFrEF. Those from group A, with PCR and DES, had a slightly higher EF, compared to the ones from group B, thus the difference was not statistically significant (p=0.056). This aspect could be explained by the fact that in the first group there were younger patients, but, on the other hand, they were more likely to have multivessel disease and diabetes mellitus, both conditions associated with HFrEF.

88.88% of our patients with DES were diabetics. In a study regarding outcomes of PCR with stenting in diabetic patients [12] concluded that the consequences of PCR are less favorable in diabetics compared with non-diabetic patients. New angioplasty techniques, such as DES, could improve the results of PCR in diabetic patients.

Other authors debate upon the effectiveness of the new generation of DES on the LV systolic function [13, 14] and the prevalence of HFrEF and the outcomes of patients with diabetes mellitus, both conditions associated with HFrEF. European Heart Journal, 40, nr. 2, 2019, p. 187-165.

The prevalence of HFrEF and the outcomes of patients treated with DES versus BMS were analysed in several studies. For example, Lagerqvist in a study realised by using data from the Swedish Coronary Angiography and Angioplasty Registry, analyzed clinical particularities and mortality at 3 years of 6033 patients treated with DES and of 13,738 with BMS and concluded that the mortality was higher in patients with DES [5].

Several meta-analysis provides evidence that revascularization, irrespective of modality, compared with medical therapy, significantly improves survival and other outcomes in patients with EF ≤40% and significant CAD [1, 18]. CABG seems to be a more favorable option [18], although a network meta-analysis of 100 trials with 93,553 patients reported that PCR with new-generation DES resulted in better outcomes compared with initial medical treatment [1].

Conclusions

Although patients with HFrEF treated by PCR and DES had more severe HD, with multivessel disease and a higher incidence of diabetes mellitus compared to those with BMS, EF was higher in the first group, possibly due to the benefits offered by the polymer-coated stents.

Table 3

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>PCR and DES 18</th>
<th>PCR and BMS 33</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60 (55-65)</td>
<td>68 (60-70)</td>
<td>0.004</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>27 (24.75-29.45)</td>
<td>27.5 (25-29)</td>
<td>0.906 - ns</td>
</tr>
<tr>
<td>Heart rate (b/min)</td>
<td>65 (60-70)</td>
<td>65 (60-70)</td>
<td>0.902 - ns</td>
</tr>
<tr>
<td>Number of stents</td>
<td>1 (1-2)</td>
<td>1 (1-1)</td>
<td>0.417 - ns</td>
</tr>
<tr>
<td>Time since last stenting (months)</td>
<td>12 (10-14.25)</td>
<td>19 (15.5-21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Repeated PCR</td>
<td>3 (27.77%)</td>
<td>6 (18.18%)</td>
<td>0.417 - ns</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>27.04 (22.81-31.91)</td>
<td>25.72 (21.7-25.64)</td>
<td>0.056 - ns</td>
</tr>
</tbody>
</table>

Legend: PCR - percutaneous coronary artery revascularization; DES - drug-eluting stent; BMS - bare-metal stent; LVEF - left ventricular ejection fraction. Mann Whitney U test.

References

Manuscript received: 16.12.2018